RESUMEN
Spinal cord injury (SCI) suffers from a lack of effective therapeutic strategies. We have previously shown that individual therapeutic strategies, transplantation of ependymal stem/progenitor cells of the spinal cord after injury (epSPCi) or FM19G11 pharmacological treatment, induce moderate functional recovery after SCI. Here, the combination of treatments has been assayed for functional and histological analysis. Immediately after severe SCI, one million epSPCi were intramedullary injected, and the FM19G11 compound or dimethyl sulfoxide (DMSO) (as the vehicle control) was administrated via intrathecal catheterization. The combination of treatments, epSPCi and FM19G11, improves locomotor tasks compared to the control group, but did not significantly improve the Basso, Beattie, Bresnahan (BBB) scores for locomotor analysis in comparison with the individual treatments. However, the histological analysis of the spinal cord tissues, two months after SCI and treatments, demonstrated that when we treat the animals with both epSPCi and FM19G11, an improved environment for neuronal preservation was generated by reduction of the glial scar extension. The combinatorial treatment also contributes to enhancing the oligodendrocyte precursor cells by inducing the expression of Olig1 in vivo. These results suggest that a combination of therapies may be an exciting new therapeutic treatment for more efficient neuronal activity recovery after severe SCI.
Asunto(s)
Benzamidas/uso terapéutico , Neuronas/metabolismo , Traumatismos de la Médula Espinal/terapia , Trasplante de Células Madre , Animales , Benzamidas/farmacología , Diferenciación Celular/efectos de los fármacos , Epéndimo/citología , Femenino , Inyecciones Espinales , Locomoción/efectos de los fármacos , Microscopía Fluorescente , Neuronas/citología , Oligodendroglía/citología , Oligodendroglía/metabolismo , Ratas , Ratas Sprague-Dawley , Recuperación de la Función , Índice de Severidad de la Enfermedad , Médula Espinal/patología , Traumatismos de la Médula Espinal/metabolismo , Traumatismos de la Médula Espinal/patología , Células Madre/citología , Células Madre/metabolismoRESUMEN
[This corrects the article DOI: 10.1016/j.isci.2021.103463.].
RESUMEN
Amyotrophic lateral sclerosis/frontotemporal dementia (ALS/FTD) is a fatal neurodegenerative disorder, and continued innovation is needed for improved understanding and for developing therapeutics. We have created next-generation genomically humanized knockin mouse models, by replacing the mouse genomic region of Sod1, Tardbp (TDP-43), and Fus, with their human orthologs, preserving human protein biochemistry and splicing with exons and introns intact. We establish a new standard of large knockin allele quality control, demonstrating the utility of indirect capture for enrichment of a genomic region of interest followed by Oxford Nanopore sequencing. Extensive analysis shows that homozygous humanized animals only express human protein at endogenous levels. Characterization of humanized FUS animals showed that they are phenotypically normal throughout their lifespan. These humanized strains are vital for preclinical assessment of interventions and serve as templates for the addition of coding or non-coding human ALS/FTD mutations to dissect disease pathomechanisms, in a physiological context.
RESUMEN
A wide range of genetic mouse models is available to help researchers dissect human disease mechanisms. Each type of model has its own distinctive characteristics arising from the nature of the introduced mutation, as well as from the specific changes to the gene of interest. Here, we review the current range of mouse models with mutations in genes causative for the human neurodegenerative disease amyotrophic lateral sclerosis. We focus on the two main types of available mutants: transgenic mice and those that express mutant genes at physiological levels from gene targeting or from chemical mutagenesis. We compare the phenotypes for genes in which the two classes of model exist, to illustrate what they can teach us about different aspects of the disease, noting that informative models may not necessarily mimic the full trajectory of the human condition. Transgenic models can greatly overexpress mutant or wild-type proteins, giving us insight into protein deposition mechanisms, whereas models expressing mutant genes at physiological levels may develop slowly progressing phenotypes but illustrate early-stage disease processes. Although no mouse models fully recapitulate the human condition, almost all help researchers to understand normal and abnormal biological processes, providing that the individual characteristics of each model type, and how these may affect the interpretation of the data generated from each model, are considered and appreciated.
Asunto(s)
Esclerosis Amiotrófica Lateral/genética , Esclerosis Amiotrófica Lateral/fisiopatología , Modelos Animales de Enfermedad , Animales , Marcación de Gen , Ratones Transgénicos , Mutagénesis/genética , Mutación/genéticaRESUMEN
The performance of graphite//LiNi0.5 Mn1.5 O4 (LNMO) cells, both electrodes of which are made using water-soluble sodium carboxymethyl cellulose (CMC) binder, is reported for the first time. The full cell performed outstandingly over 400â cycles in the conventional electrolyte ethylene carbonate/dimethyl carbonate-1 m LiPF6 , and the delivered specific energy at the 100th, 200th, 300th, and 400thâ cycle corresponded to 82, 78, 73, and 66 %, respectively, of the initial energy value of 259â Wh kg-1 (referring to the sum of the two electrode-composite weights). The good stability of high-voltage, LNMO-CMC-based electrodes upon long-term cycling is discussed and the results are compared to those of LNMO-composite electrodes with polyvinylidene fluoride (PVdF). LNMO-CMC electrodes outperformed those with PVdF binder, displaying a capacity retention of 83 % compared to 62 % for the PVdF-based electrodes after 400â cycles at 1 C. CMC promotes a more compact and stable electrode surface than PVdF; undesired interfacial reactions at high operating voltages are mitigated, and the thickness of the passivation layer on the LNMO surface is reduced, thereby enhancing its cycling stability.
Asunto(s)
Suministros de Energía Eléctrica , Grafito/química , Tecnología Química Verde , Óxidos/química , Agua/química , Carboximetilcelulosa de Sodio/química , Electroquímica , Electrodos , Compuestos de Manganeso/química , Níquel/químicaRESUMEN
Rheumatological manifestations of Diabetes Mellitus may be classified in: non articular, articular and bone conditions. Among non articular conditions, diabetic cheiroarthropathy, frequent in type I diabetes, the most important disorder related to limited joint mobility, results in stiff skin and joint contractures. Adhesive capsulitis of the shoulder, flexor tenosynovitis, and Duputryen's and Peyronie's diseases are also linked to limited joint mobility. Diffuse skeletal hyperostosis, due to calcification at entheses, is frequent and early, particularly in type 2 diabetes. Neuropathies cause some non articular conditions, mainly neuropathic arthritis, a destructive bone and joint condition more common in type I diabetes. Algodistrophy, shoulder-hand and entrapment syndromes are also frequent. Mononeuropathy causes diabetic amyotrophy, characterised by painless muscle weakness. Among muscle conditions, diabetic muscle infarction is a rare, sometimes severe, condition. Among articular conditions, osteoarthritis is frequent and early in diabetes, in which also chondrocalcinosis and gout occur. Rheumatoid arthritis (RA) and diabetes I have a common genetic background and the presence of diabetes gives to RA an unfavourable prognosis. Among bone conditions, osteopenia and osteoporosis may occur early in type 1 diabetes. Contrarily, in type 2 diabetes, bone mineral density is similar or, sometimes, higher than in non diabetic subjects, probably due to hyperinsulinemia.